Nintedanib Al (Nintedanib)

Nintedanib blocks the activity of several receptor tyrosine kinases, notably VEGFR 1‑3, PDGFR α/β and FGFR 1‑3. Inhibiting these receptors reduces fibroblast proliferation, migration and transformation, and also limits abnormal blood‑vessel formation, thereby mitigating fibrotic tissue development and tumour growth.

The exact dose of Nintedanib Al is set by the prescribing clinician based on the specific indication, patient characteristics, liver function, and any concomitant medications. Dosage adjustments are made according to clinical response and tolerability, and patients should follow the prescriber’s instructions precisely.

Safety data for Nintedanib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with an obstetric specialist. Breastfeeding is generally not recommended while receiving Nintedanib.

To request Nintedanib Al, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, another antifibrotic agent. While both aim to slow disease progression, Nintedanib targets multiple tyrosine‑kinase pathways, offering broader anti‑angiogenic activity, whereas pirfenidone works mainly through modulation of inflammatory and oxidative pathways. Choice of therapy depends on patient tolerance, comorbidities and physician assessment.

Nintedanib Al should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in areas of high humidity or direct sunlight, and keep out of reach of children.

Nintedanib Al is taken orally, usually with a full glass of water. It is generally recommended to swallow the capsule whole and not to crush or chew it. Dosing times (e.g., with food) should follow the prescriber’s guidance to optimise absorption and minimise gastrointestinal discomfort.

The most serious adverse events associated with Nintedanib include hepatotoxicity (significant elevation of liver enzymes or liver failure), severe bleeding events, arterial thromboembolism, and rare gastrointestinal perforation. Patients should be monitored regularly for liver function, signs of bleeding, and any acute abdominal pain.

Nintedanib is contraindicated in patients with known hypersensitivity to the active substance or any excipients, those with active severe liver disease, uncontrolled bleeding disorders, or recent major arterial thrombotic events. Caution is also advised for patients on strong CYP3A4 inhibitors, and it should be avoided in pregnancy unless absolutely necessary.